M1-like macrophage exosomes with OX40L overexpressed for cancer immunotherapy

Gene Editing Services

Ubigene has modified over 5000 genes from more than 200 cell lines with our exclusive innovation CRISPR-U™ technology. At the same time, we already provide customers with high quality gene-editing tools for cell or animal research worldwide.

Stable Cell Lines

Knockout Cell Lines

Knockin Cell Lines

Overexpression Cell Lines

Knockdown Cell Lines

iPSC and ESC Gene editing

Cloning Services

Knockout Plasmid

Point Mutation Plasmid

Knockin Plasmid

Overexpression Plasmid

Knockdown Plasmid

Virus Packaging

Lentivirus Packaging

Adenovirus Packaging

Adeno-associated Virus Packaging

CRISPR Library

CRISPR Library In-stock

Customized CRISPR Library

CRISPR Library Screening

Microbe

Gene-editing E.coli

Gene-editing Salmonella

Gene-editing P. aeruginosa

Gene-editing S. aureus

Cell Assay

Cell Proliferation

Cell Migration and Invasion

Cell Cycle

Cell Apoptosis

Detection of Marker Protein Expression

Cytokine Secretion and Enzyme Activity Test

Cytotoxicity Test

EZ-editor™
Gene-editing Series Products

With 14 years of experience, Ubigene has exclusively innovated and developed 6 product lines, fullfilling all kinds of needs from researchers. Experiment process simplified, efficiency improved, achieving our aim of 'Make genome editing easier'!

Red Cotton™ gRNA Plasmid Bank

Regular Plasmid

Lentiviral Plasmid

EZ-editor™ Culture Medium

Transfection Culture Medium

Cell Monoclonal Culture Medium

EZ-Stem™ Cell Culture Medium

EZ-cryo™ Cell Freezing Medium

Knockout-cell-lysate

KO cell lysates (clone)

KO cell lysates (pool)

EZ-editor™ Cell Line

KO Cell Lines

Wild-type Cell Lines

Cas9 Stable Cell Lines

Luciferase Stable Cell Lines

EGFP Stable Cell Lines

EZ-editor™ Kits

Monoclone Genotype Validation Kit (extraction free)

EZ-editor™ Gene Knockout kit

Mouse Genotyping Kit

Lentiviral Packaging Kit

Lentivirus

IVD positive controls

Point Mutation gDNA/Cell Line

Red Cotton Gene knockout Project

Ubigene exclusive KO Cell Line Bank, over 5000 KO cell lines, covering thousands of genes from 8 popular signaling pathways and nearly 100 diseases.

Red Cotton CRISPR Gene Editing Designer

Gene Editing Cell Designer

Gene Editing Point Mutation Designer

Gene Editing Microbe Designer

Gene Editing Tool Kit

Red Cotton Gene knockout Project

Location：Home > Application > M1-like macrophage exosomes with OX40L overexpressed for cancer immunotherapy

Contact us✖

* Name：

Institution：

* Project Description：

* How would you like us to contact you?

* E-mail：

Phone：

WhatsAPP：

FaceBook Messenger：

Our Solution Specialists will contact you within 2 business days. Of course, you can also tell us when you would like to be contacted:

Select：

M1-like macrophage exosomes with OX40L overexpressed for cancer immunotherapy

M1-like macrophage exosomes with OX40L overexpressed for cancer immunotherapy

Cancer is still one of the main factors threatening human life and health safety. Although current immunotherapy represented by PD-1/PD-L1 inhibitors has achieved great success, patients' benefit is limited. Developing new immunotherapies may be one of the directions to solve the current cancer treatment dilemma.

Recently, researchers from several institutes including the Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Sun Yat sen University, China published an original research paper entitled "OX40L-expressing M1-like macrophage exosomes for cancer immunotherapy" on Journal of controlled release (JCR Q1 IF:10.8). In this study, EGFP-OX40L overexpressing stable cells constructed by Ubigene were used to develop a novel engineered M1-like macrophage exosomeOX40L M1-exos for cancer immunotherapy.

Schematic illustration of the preparation of the OX40L M1-exos and its anticancer effect

Figure 1. Schematic illustration of the preparation of the OX40L M1-exos and its anticancer effect

In this study, the researchers developed the M1-like macrophage exosomes with overexpressing OX40L: OX40L M1-exos using biotechnology including gene-related cell engineering. OX40L M1-exos can activate T cell-mediated adaptive immunity through OX40/OX40L pathway; and can reprogram M2-like tumor-associated macrophages into M1-like macrophages, thereby restoring and enhancing macrophage-mediated innate immunity. In animal models, OX40L M1-exos effectively achieved the synergistic effect of innate and adaptive immunity, significantly inhibited the growth and spontaneous metastasis of breast cancer in mice, and prolonged the survival of mice.

Evaluation of the effect of inhibiting tumor growth and metastasis in vivo

Figure 2. Evaluation of the effect of inhibiting tumor growth and metastasis in vivo

In addition, OX40L M1-exos is also used as a drug loading platform for drug delivery, providing a platform and method for combined therapy with other drugs (such as some small molecule drugs). In conclusion, OX40L M1-exos provides a novel and effective strategy for tumor immunotherapy.